Clinical efficacy of chidamide combined with BEAC preconditioning regimen in high-risk or refractory diffuse large B-cell lymphoma receiving autologous hematopoietic stem cell transplantation
10.3760/cma.j.cn115356-20221217-00354
- VernacularTitle:高危或难治弥漫大B细胞淋巴瘤自体造血干细胞移植采用西达本胺联合BEAC方案预处理的临床疗效
- Author:
Yanna MENG
1
;
Cixian ZHANG
Author Information
1. 徐州市中心医院血液科,徐州 221009
- Keywords:
Lymphoma, large B-cell, diffuse;
Hematopoietic stem cell transplantation;
Transplantation conditioning;
Chidamide;
BEAC regimen
- From:
Journal of Leukemia & Lymphoma
2023;32(8):473-476
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of chidamide combined with BEAC (camustine+etoposide+ cytarabine+cyclophosphamide) preconditioning regimen in high-risk or refractory diffuse large B-cell lymphoma (DLBCL) receiving autologous stem cell transplantation.Methods:The clinical data of 10 high-risk or refractory DLBCL patients with autologous stem cell transplantation after receiving chidamide combined with BEAC preconditioning regimen who were admitted to Xuzhou Central Hospital from March 2022 to May 2023 were retrospectively analyzed. The related complications during preconditioning and hematopoietic reconstruction process, the time of hematopoietic stem cell reconstruction after transplantation, and the short-term efficacy were summarized.Results:Of the 10 patients, 6 were women and 4 were men; the median age was 58 years old (27-68 years old). Hematopoietic reconstruction was achieved in all 10 patients after transplantation. The median time of neutrophil engraftment was 11 d (range 7-12 d), and the median time of platelet engraftment was 12 d (range 9-16 d) after transplantation. Hematological adverse reactions were described as follows: 2 cases had grade 3 febrile neutropenia, 1 case had grade 4 febrile neutropenia, 3 cases had grade 2 anemia, and 1 case had grade 3 anemia. Non-hematological adverse reactions were described as follows: 1 case had grade 2 nausea with vomiting, and 1 case had diarrhea. Eight patients were followed-up for >3 months after transplantation, 6 patients achieved complete remission, 1 patient achieved partial remission, and 1 patient with TP53 deletion developed disease progression 1 month after transplantation.Conclusions:Autologous hematopoietic stem cell transplantation with chidamide combined with BEAC preconditioning regimen is effective for patients with high-risk or refractory DLBCL, and the adverse reactions are tolerable.